Founded in 2013, Lunit is a medical AI business based in South Korea that specializes in AI-powered cancer diagnostic and treatment solutions. To help medical practitioners make more precise and effective clinical judgments, its key solutions, Lunit INSIGHT and Lunit SCOPE, use deep learning to evaluate tissue data and medical pictures, respectively.

Mammography and chest X-ray analysis tools are included in Lunit INSIGHT, which has a high accuracy rate in identifying anomalies and early-stage malignancies. Lunit SCOPE helps forecast treatment responses by focusing on AI biomarkers for immunotherapy. These solutions are used in more than 3,000 healthcare facilities in more than 50 countries and have received FDA and CE certifications.

When Lunit went public on the KOSDAQ in July 2022 under the ticker “A328130,” it was a major step forward in its goal to use AI to transform cancer treatment. In order to promote precision medicine, the company keeps growing its worldwide footprint and research projects while working with top pharmaceutical and healthcare organizations.